DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
Cabergoline
/ pharmacology
Drug Interactions
Everolimus
/ pharmacology
Humans
Neuroendocrine Tumors
/ drug therapy
Pituitary Neoplasms
/ drug therapy
Proto-Oncogene Proteins c-akt
/ metabolism
Receptors, Dopamine D2
/ agonists
TOR Serine-Threonine Kinases
/ antagonists & inhibitors
beta-Arrestin 2
/ metabolism
AKT phosphorylation
cabergoline
dopamine receptor type 2
everolimus
mTOR inhibitors
pituitary neuroendocrine tumors
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
02
2022
accepted:
04
04
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
22
6
2022
Statut:
epublish
Résumé
The mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to display antiproliferative effects on a wide spectrum of tumors.
Identifiants
pubmed: 35721701
doi: 10.3389/fendo.2022.867822
pmc: PMC9204243
doi:
Substances chimiques
DRD2 protein, human
0
Receptors, Dopamine D2
0
beta-Arrestin 2
0
Everolimus
9HW64Q8G6G
MTOR protein, human
EC 2.7.1.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Cabergoline
LL60K9J05T
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
867822Informations de copyright
Copyright © 2022 Mangili, Esposito, Treppiedi, Catalano, Marra, Di Muro, Barbieri, Locatelli, Lania, Mangone, Spada, Arosio, Peverelli and Mantovani.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Endocrine. 2017 Jun;56(3):603-620
pubmed: 27688013
J Clin Endocrinol Metab. 2019 Jun 1;104(6):1929-1936
pubmed: 30624667
Endocr Relat Cancer. 2014 Aug;21(4):R331-44
pubmed: 25052915
Target Oncol. 2011 Mar;6(1):17-27
pubmed: 21547705
Blood. 2009 Oct 1;114(14):2926-35
pubmed: 19641186
Recent Results Cancer Res. 2018;211:101-123
pubmed: 30069763
Endocrinology. 2009 May;150(5):2064-71
pubmed: 19116338
Int J Cancer. 2017 Apr 15;140(8):1870-1880
pubmed: 28120505
Eur J Endocrinol. 2016 Jul;175(1):63-72
pubmed: 27150495
Neuroendocrinology. 2021;111(6):568-579
pubmed: 32512568
Clin Cancer Res. 2015 Jul 15;21(14):3204-15
pubmed: 25838390
Endocr Relat Cancer. 2005 Jun;12(2):423-33
pubmed: 15947113
Cancer Lett. 2010 Feb 28;288(2):170-6
pubmed: 19619936
Blood. 2008 Jan 1;111(1):379-82
pubmed: 17878402
J Mol Endocrinol. 1995 Jun;14(3):375-89
pubmed: 7669227
Pituitary. 2018 Apr;21(2):111-118
pubmed: 29368293
Neuroendocrinology. 2016;103(5):592-604
pubmed: 26562326
Endocrinology. 2014 Sep;155(9):3538-49
pubmed: 24926820
J Clin Invest. 2017 Jun 1;127(6):2438
pubmed: 28569734
Cancer Res. 2010 Jan 15;70(2):666-74
pubmed: 20068168
J Clin Endocrinol Metab. 2010 Feb;95(2):968-76
pubmed: 19965918
Endocr Relat Cancer. 2009 Sep;16(3):1017-27
pubmed: 19509067
Pituitary. 2019 Aug;22(4):422-434
pubmed: 31011999
Cancer Res. 2006 Feb 1;66(3):1500-8
pubmed: 16452206
J Neurosci. 2007 Jan 24;27(4):881-5
pubmed: 17251429
Mol Cancer Ther. 2005 Oct;4(10):1533-40
pubmed: 16227402
J Clin Endocrinol Metab. 2009 Nov;94(11):4406-13
pubmed: 19820025
Blood. 2010 Jun 3;115(22):4455-63
pubmed: 20299510
Acta Neuropathol. 2017 Oct;134(4):521-535
pubmed: 28821944
Trends Cell Biol. 2003 Feb;13(2):79-85
pubmed: 12559758
Science. 2005 Feb 18;307(5712):1098-101
pubmed: 15718470